Page last updated: 2024-12-08
19-hydroxydeoxycorticosterone
Description
## 19-Hydroxydeoxycorticosterone (19-OH-DOC)
19-Hydroxydeoxycorticosterone (19-OH-DOC) is a steroid hormone that is a precursor to aldosterone, a key hormone in regulating blood pressure and electrolyte balance.
**Here's a breakdown:**
* **Structure:** 19-OH-DOC is a derivative of deoxycorticosterone (DOC), with an additional hydroxyl group at the 19th carbon position.
* **Synthesis:** 19-OH-DOC is synthesized in the adrenal glands, specifically in the zona glomerulosa, the outermost layer of the adrenal cortex.
* **Role:** 19-OH-DOC is an intermediate in the synthesis of aldosterone. It is converted to aldosterone by the enzyme aldosterone synthase.
* **Clinical Significance:** 19-OH-DOC itself has minimal biological activity. However, its role as a precursor to aldosterone makes it important for studying aldosterone synthesis and related conditions.
**Importance in Research:**
19-OH-DOC is important for research due to its involvement in various physiological and pathological processes:
* **Aldosterone Synthesis:** Researchers study 19-OH-DOC to understand the regulation of aldosterone production. This includes investigating the activity of aldosterone synthase and the factors that influence its activity.
* **Hypertension and Sodium Retention:** 19-OH-DOC levels can be elevated in conditions associated with high blood pressure and sodium retention, like Conn's syndrome.
* **Drug Development:** 19-OH-DOC serves as a target for developing drugs that modulate aldosterone synthesis. This could be helpful in managing hypertension and other cardiovascular diseases.
* **Endocrine Disorders:** 19-OH-DOC levels can be measured to diagnose and monitor various endocrine disorders, such as adrenal insufficiency and adrenal hyperplasia.
* **Steroid Hormone Metabolism:** Research on 19-OH-DOC provides insights into the complex pathways of steroid hormone metabolism and the factors that influence their production and breakdown.
**In conclusion:**
19-OH-DOC is a crucial intermediate in the synthesis of aldosterone, a hormone vital for maintaining blood pressure and electrolyte balance. Its importance in research lies in its role in understanding aldosterone synthesis, developing new therapies for cardiovascular disease, and diagnosing and monitoring various endocrine disorders.
19-hydroxydeoxycorticosterone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 164961 |
CHEBI ID | 195167 |
SCHEMBL ID | 8206917 |
MeSH ID | M0090184 |
Synonyms (11)
Synonym |
2394-23-2 |
pregn-4-ene-3,20-dione, 19,21-dihydroxy- |
19-hydroxydeoxycorticosterone |
19,21-dihydroxyprogesterone |
19-oh-doc |
CHEBI:195167 |
SCHEMBL8206917 |
LFISWQXWWGJHBL-ZOCXKQACSA-N |
19,21-dihydroxypregn-4-ene-3,20-dione # |
(2s,14s,15s)-14-(2-hydroxyacetyl)-2-(hydroxymethyl)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one |
DTXSID20946759 |
Drug Classes (4)
Class | Description |
19-hydroxydeoxycorticosterone | |
20-oxo steroid | An oxo steroid carrying an oxo group at position 20. |
21-hydroxy steroid | |
3-oxo-Delta(4) steroid | A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 7 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.25 (24.57) | Research Supply Index | 2.20 (2.92) | Research Growth Index | 4.45 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |